JP2021530498A - ＣＤ３８を標的とする改変Ｆｃ抗原結合ドメイン構築体に関する組成物および方法 - Google Patents

ＣＤ３８を標的とする改変Ｆｃ抗原結合ドメイン構築体に関する組成物および方法 Download PDF

Info

Publication number
JP2021530498A
JP2021530498A JP2021500858A JP2021500858A JP2021530498A JP 2021530498 A JP2021530498 A JP 2021530498A JP 2021500858 A JP2021500858 A JP 2021500858A JP 2021500858 A JP2021500858 A JP 2021500858A JP 2021530498 A JP2021530498 A JP 2021530498A
Authority
JP
Japan
Prior art keywords
domain
polypeptide
domain monomer
monomer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021500858A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020014526A5 (https=
JP2021530498A5 (https=
Inventor
アンソニー マニング
アミット チョードゥリー
ダニエル オルティス
ジョナサン シー． ランシング
Original Assignee
モメンタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モメンタ ファーマシューティカルズ インコーポレイテッド filed Critical モメンタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2021530498A publication Critical patent/JP2021530498A/ja
Publication of JPWO2020014526A5 publication Critical patent/JPWO2020014526A5/ja
Publication of JP2021530498A5 publication Critical patent/JP2021530498A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021500858A 2018-07-11 2019-07-11 ＣＤ３８を標的とする改変Ｆｃ抗原結合ドメイン構築体に関する組成物および方法 Withdrawn JP2021530498A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862696759P 2018-07-11 2018-07-11
US62/696,759 2018-07-11
US201862733036P 2018-09-18 2018-09-18
US62/733,036 2018-09-18
US201862744067P 2018-10-10 2018-10-10
US62/744,067 2018-10-10
PCT/US2019/041468 WO2020014526A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38

Publications (3)

Publication Number Publication Date
JP2021530498A true JP2021530498A (ja) 2021-11-11
JPWO2020014526A5 JPWO2020014526A5 (https=) 2022-07-15
JP2021530498A5 JP2021530498A5 (https=) 2022-07-15

Family

ID=69141927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500858A Withdrawn JP2021530498A (ja) 2018-07-11 2019-07-11 ＣＤ３８を標的とする改変Ｆｃ抗原結合ドメイン構築体に関する組成物および方法

Country Status (11)

Country Link
US (1) US20210269546A1 (https=)
EP (1) EP3820516A4 (https=)
JP (1) JP2021530498A (https=)
KR (1) KR20210044218A (https=)
CN (1) CN113194990A (https=)
AU (1) AU2019299973A1 (https=)
BR (1) BR112021000416A2 (https=)
CA (1) CA3106142A1 (https=)
IL (1) IL280046A (https=)
MX (1) MX2021000307A (https=)
WO (1) WO2020014526A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CN118591388A (zh) * 2021-09-29 2024-09-03 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
CN115873127B (zh) * 2021-11-26 2026-04-10 深圳科兴药业有限公司 重组长效人生长激素融合蛋白及其制备方法和用途
EP4448585A4 (en) * 2021-12-17 2026-02-25 Modex Therapeutics Inc ANTIGEN-BINDING POLYPEPTIDE COMPLEXES CONTAINING EXTRACELLULAR DOMAINS OF TNFSF LIGANDS
WO2025229158A1 (en) * 2024-05-01 2025-11-06 Commit Biologics Aps Antibodies and antibody constructs against cd38

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140242081A1 (en) * 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
EP2748197A2 (en) * 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
KR20200024345A (ko) * 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
AU2015358615B2 (en) * 2014-12-04 2021-08-05 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
CA2994746A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
WO2017151971A2 (en) * 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
BR112018074056A2 (pt) * 2016-05-23 2019-03-06 Momenta Pharmaceuticals, Inc. composições e métodos relacionados a construtos de fc manipulados
CA3043251A1 (en) * 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds

Also Published As

Publication number Publication date
MX2021000307A (es) 2021-09-08
CA3106142A1 (en) 2020-01-16
KR20210044218A (ko) 2021-04-22
BR112021000416A2 (pt) 2021-04-06
US20210269546A1 (en) 2021-09-02
CN113194990A (zh) 2021-07-30
AU2019299973A1 (en) 2021-02-18
EP3820516A4 (en) 2022-04-20
WO2020014526A2 (en) 2020-01-16
WO2020014526A3 (en) 2020-02-20
EP3820516A2 (en) 2021-05-19
IL280046A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
JP2021530498A (ja) ＣＤ３８を標的とする改変Ｆｃ抗原結合ドメイン構築体に関する組成物および方法
JP2021532085A (ja) ＣＴＬＡ−４を標的とする改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
JP2020514301A (ja) 改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
US20220267460A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
JP2021530989A (ja) ＰＤ−Ｌ１を標的とした改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
JP2021531756A (ja) ＣＣＲ４を標的指向する改変Ｆｃ抗原結合ドメイン構築体に関する組成物および方法
JP2021530992A (ja) 改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
JP2021531757A (ja) 改変されたＦｃ−抗原結合ドメイン構築体に関する組成物および方法
JP2021531755A (ja) 改変されたＦｃ−抗原結合ドメイン構築物に関する組成物および方法
JP2022548925A (ja) ＣＤ３８を標的とした改変されたＦｃ抗原結合ドメイン構築物に関する組成物及び方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210420

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210526

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220707

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220907